Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Jun Masuda
Observed name:
J. Masuda
Institutions:
The Cancer Institute Hospital,
Japanese Foundation For Cancer Research
Observed institutions:
The Cancer Institute Hospital,
Japanese Foundation For Cancer Research
ORCID:
0000-0002-0972-1926
Observed ORCID:
0000-0002-0972-1926
OpenAlex ID:
A5028264522
Efficacy and feasibility of neoadjuvant pembrolizumab plus chemotherapy for early-stage triple-negative and estrogen receptor low, HER2-negative breast cancer: a Japanese single-institution real-world study
2024
·
Yosuke Aoyama
, Yukinori Ozaki
, et al.
·
Breast Cancer
·
11
The impact of obesity and endocrine therapy on the prognosis of premenopausal women with hormone receptor‐positive breast cancer: A single‐institute retrospective study
2022
·
Yukinori Ozaki
, Jun Masuda
, et al.
·
Cancer Reports
·
11
Risk factors and long-term prognostic impact of trastuzumab deruxtecan-related interstitial lung disease in metastatic breast cancer.
2026
·
Takayuki Kobayashi
, Meiko Nishimura
, et al.
·
Journal of Clinical Oncology
·
1
Cytokine-mediated hypersensitivity reactions to carboplatin in early triple-negative breast cancer with neoadjuvant pembrolizumab plus chemotherapy.
2025
·
Masahiro Kuno
, Yosuke Aoyama
, et al.
·
Journal of Clinical Oncology
·
1
PDF
Time to maximal response of trastuzumab deruxtecan in patients with HER2-Positive metastatic breast cancer: A multicenter retrospective study (TRACE)
2026
·
Yukinori Ozaki
, Emi Taniguchi
, et al.
·
The Breast
S-1 versus capecitabine as first-line chemotherapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer in the era of cyclin-dependent kinase 4/6 inhibitors: a retrospective cohort study
2026
·
Takayuki Kobayashi
, Meiko Nishimura
, et al.
·
BMC Cancer
Real-world event-free survival with neoadjuvant pembrolizumab plus chemotherapy and adjuvant pembrolizumab in early-stage triple-negative and estrogen receptor-low, HER2-negative breast cancer
2026
·
Yosuke Aoyama
, Yukinori Ozaki
, et al.
·
BMC Cancer
Real-world outcomes of datopotamab deruxtecan after trastuzumab deruxtecan in hormone receptor–positive, HER2-negative metastatic breast cancer
2026
·
Yosuke Aoyama
, Yukinori Ozaki
, et al.
·
Breast Cancer
PDF
AI-integrated multi-omics platform to revolutionize anti-metastatic therapy development through circulating tumor cell profiling: SCRUM-MONSTAR-CTC
2026
·
Tadayoshi Hashimoto
, Taro Shibuki
, et al.
·
International Journal of Clinical Oncology
PDF
Prospective study of a novel portable scalp-cooling cap for prevention of chemotherapy-induced alopecia.
2026
·
Yosuke Aoyama
, Takehiko Sakai
, et al.
·
Journal of Clinical Oncology
Clinical benefits of early-phase clinical trials for rare malignancies: Asian single-center analysis.
2026
·
Akihiro Ohmoto
, Takahiro Kogawa
, et al.
·
Journal of Clinical Oncology
Efficacy of datopotamab deruxtecan after trastuzumab deruxtecan in metastatic hormone receptor–positive HER2-negative breast cancer: A real-world study.
2026
·
Yosuke Aoyama
, Yukinori Ozaki
, et al.
·
Journal of Clinical Oncology
PDF
Abstract PS4-01-12: Androgen receptor and FOXA1 in breast cancer: Prognostic insights from a treatment-naïve historical cohort
2026
·
Y. Inoue
, T. Osako
, et al.
·
Clinical Cancer Research
Abstract PS5-07-07: Toward optimization of treatment strategies for early breast cancer: a multicenter observational study integrating whole genome and transcriptome sequencing within the National Whole Genome Project in Japan (WJOG16822B)
2026
·
J. Masuda
, Y. Ozaki
, et al.
·
Clinical Cancer Research
Real-world pathological outcomes after neoadjuvant chemotherapy with subcutaneous versus intravenous pertuzumab and trastuzumab in HER2-positive early breast cancer
2026
·
Haruka Ozaki
, Jun Masuda
, et al.
·
SSRN Electronic Journal
PDF
Retrospective analysis of survival of patients with HER2-positive breast cancer with microscopic residual invasive disease after neoadjuvant chemotherapy
2025
·
Meiko Nishimura
, Takayuki Kobayashi
, et al.
·
Breast Disease
[National Cancer Control in a Super-Aged Society-Based on the Fourth Basic Plan to Promote Cancer Control].
2025
·
Rika Kizawa
, Genki Kanagawa
, et al.
·
PubMed
Abstract P4-11-06: Effect of suppressed ovarian function on prognosis of premenopausal obese women with hormone receptor-positive breast cancer: A single-institute retrospective study
2022
·
Yukinori Ozaki
, Jun Masuda
, et al.
·
Cancer Research
Abstract OT2-19-02: Clinical evaluation of the efficacy and liquid molecular analysis of abemaciclib rechallenge upon progression to abemaciclib combination therapies for ER-positive HER2-negative metastatic breast cancer patients
2022
·
Meiko Nishimura
, Takahiro Kogawa
, et al.
·
Cancer Research
Show more works
View as search
Works count:
19
Citation count:
24
H-index:
2
I10-index:
2
Year
Topic
Type